Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Kangstem Biotech
We are making the world where everyone can live a healthy and happy life.
- Company Name : Kangstem Biotech., Ltd.
- Establish : October 29, 2010
- Headquarter Location : 9th Floor, Hongwoo Bldg., 522 Teheran-ro, Gangnam-gu, Seoul
- Telephone : +82-2-888-1590
Business Area
Stem Cell Therapy Business
Organoid Business
JUVENTAS
Stem Cell Culture Business
CDMO
Health & Beauty Business
History
2021
07Granted a license for the management of human cells etc.
05Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
04Entered into MOU with Seoul National University Bundang Hospital
02Acquisition of cosmetics business
2020
- 12Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
- 04Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
2019
03Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
2018
- 02Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
2017
09Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
2016
- 10Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
- 10Nominated by The Ministry of Trade, Industry and Energy as a "K-BrainPower" company
- 02Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
2015
12Listed on KOSDAQ
08Concluded the contract of iNSC technology joint business with Orig3n of the U.S
08Expanded the Construction of Stem Cell GMP Center
08Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
07Acquired ISO certificates (ISO 9001, ISO 14001)
06Selected for the future industry leading technology development business – R&D for cell culture system
01Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
2014
- 12Approved of Furestem-CD® Phase 1 (added psoriasis indicant)
- 12Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
- 09Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
- 06Certified for Technology INNO-BIZ
- 05Approved of Furestem-RA® Phase 1
2013
12Changed business name to Kangstem Biotech
10Selected for the parts material business – GvHD preclinical
06Approved of Furestem-CD® Phases 1 & 2a
01Approved of Furestem-AD® Phases 1 & 2a
2012
- 12Selected for the public health medical research development business - Psoriasis preclinical
- 05Selected for the public health medical study development business - Crohn’s disease preclinical
- 02Completed the construction of Stem Cell GMP Center
2011
12Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
08Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
02Certified for the venture company by KIBO (Korea Technology Finance Corporation)
2010
- 10Established Kangstem Holdings
